Glenmark Pharma gets USFDA approval for prostate cancer treatment drug .The approved product is a generic version of Zytiga tablets, 250 mg, of Janssen Biotech

Drug firm Glenmark Pharmaceuticals on Thursday said it has received final approval from the US health regulator for Abiraterone Acetate tablets used to treat prostate cancer.

The approved product is a generic version of Zytiga tablets, 250 mg, of Janssen Biotech. "Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (USFDA) for Abiraterone Acetate tablets USP, 250 mg," the company said in a regulatory filing. 

Citing IQVIA deals information for the year time frame finishing August 2019, Glenmark said the Zytiga tablets, 250 mg market accomplished yearly offers of roughly USD 794.1 million.

Glenmark's present portfolio comprises of 162 items approved for dissemination in the US commercial center and 46 ANDA's pending endorsement with the USFDA.

Portions of Glenmark Pharma were exchanging 0.15 percent higher at Rs 286.00 each on the BSE.

 Feel free to send me comments about this article.